Home
What the FDA Feedback Means for Antisense Therapeutics (ASX:ANP)
PUBLISHED
2021-06-04
Content
Former Chief Medical Officer for CSL Charmaine Gittleson gives some insights into why she joined the ANP board, the way the FDA process works, and how this Type C meeting fits into clarifying the pathway to starting a clinical trial.
To access and download the latest research on ANP, go to https://www.sharecafe.com.au/company/antisense-therapeutics-limited/